Press releases

November 18, 2015 Invitae Announces Expansion of Its Epilepsy Test Menu
- Invitae now offers an extensive genetic testing panel to better support the needs of clinicians and patients - Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has expanded its epilepsy testing menu, now offering an extensive panel with more than 100 carefully curated genes that are among the most clinically significant for this life-threatening condition. The menu also includes a smaller panel specifically for early infantile epileptic encephalopathy and one specifically for syndromic forms of epilepsy. Because Invitae offers easily customizable panels, physicians can choose to build their own panels for patients with a clinically unambiguous phenotype or where biochemical or other testing points to specific genes. For example, genes for progressive myoclonic epilepsy or creatine deficiency may be specifically selected for testing. Invitae’s epilepsy panel includes a number of genes in which discovery of pathogenic variants would guide
Read more
November 18, 2015 Invitae Announces Expansion of Hereditary Cancer Testing Menu
- Expanded offering now one of the most comprehensive and includes testing for endocrine, blood, bone, brain, genitourinary, sarcoma, and skin cancers - Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its hereditary cancer genetic testing menu, now offering an even more comprehensive testing menu that covers all major hereditary cancers. Invitae has expanded its test menu to include blood, bone, brain, endocrine (hyperparathyroidism, thyroid cancer, and paraganglioma-pheochromocytoma), genitourinary (renal/urinary tract and prostate cancer), sarcoma, and skin cancers (melanoma and basal cell nevus syndrome). This expanded test menu is offered at the same price and with the same flexibility as all of Invitae’s genetic tests. “A broad hereditary cancer testing menu provides clinicians with options, to choose a single or a set of genes. Providers have therefore a flexibility to test for a single specific syndrome, or since many
Read more
November 5, 2015 Invitae Announces Third Quarter 2015 Financial Results and Raises 2015 Volume Guidance
SAN FRANCISCO-(BUSINESS WIRE)- Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the third quarter ended September 30, 2015. The company has raised its 2015 guidance for billable tests delivered to 17,000-19,000 for the year, up from its previous guidance of 16,000-18,000 billable tests delivered. “Two years after the Supreme Court decision, we are helping to usher in a bold new landscape for hereditary testing that is based on making high quality genetics more affordable and more accessible to the mainstream medical community,” said Randy Scott , chairman and CEO of Invitae . “In the multi-billion dollar genetics industry, we are beginning to prove that providing high-quality content with low prices can help clinicians better serve their patients. This innovative positioning has led us to market share growth that we believe is also one of the fastest in the industry.” Following are recent highlights: Generated revenue of nearly $2.2 million in the
Read more
November 5, 2015 Invitae Appoints Christine M. Gorjanc to its Board of Directors
Invitae Corporation (NYSE:NVTA), a genetic information company, today announced the appointment of Christine M. Gorjanc to its Board of Directors, effective immediately. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151105005530/en/ Christine Gorjanc joins Invitae's Board of Directors (Photo: Business Wire) Christine currently serves as chief financial officer at NETGEAR, Inc. (NASDAQ: NTGR), a global networking company that delivers innovative products to consumers, businesses, and service providers. Prior to joining NETGEAR as vice president of finance in November 2005, Ms. Gorjanc served as vice president, controller, treasurer, and assistant secretary for Aspect Communications Corporation, a provider of workforce and customer management solutions from September 1996 through November 2005. From October 1988 through September 1996, she served as the manager of tax for Tandem Computers, Inc., a provider of
Read more
October 19, 2015 Invitae to Provide Testing for Sudden Death in the Young (SDY) Case Registry to Advance Understanding of Sudden Death in the Young
First-of-its-kind collaboration seeks to provide genetic insights to medical examiners and families of victims of sudden death in the young Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that it has entered into a collaboration with the Sudden Death in the Young (SDY) Case Registry, the first ever active surveillance effort designed to increase understanding of the prevalence, causes and risk factors for sudden death in the young. The Registry is funded by the National Heart, Lung, and Blood Institute (NHLBI) , the National Institute of Neurological Disorders and Stroke (NINDS) , and the Centers for Disease Control and Prevention (CDC) ; the Data Coordinating Center is at the Michigan Public Health Institute (MPHI) ; and the SDY Biorepository is at the University of Michigan (UM) . Invitae is providing comprehensive diagnostic arrhythmia genetic testing to the Registry on autopsy negative cases as in-kind services in collaboration with MPHI and UM.
Read more
October 15, 2015 Invitae to Announce Third Quarter 2015 Financial Results and Host Conference Call on November 5, 2015
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that it will report its third quarter 2015 financial results on Thursday, November 5, 2015 , and will host a conference call that day at 4:45 pm Eastern / 1:45 pm Pacific to discuss its financial results and recent developments. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 61246482. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company’s website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website. About Invitae Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate
Read more
October 7, 2015 Invitae Expands Its Neuromuscular Offering with Broad, Affordable Panels and New Testing Categories for Patients
- Now offering high-quality, affordable genetic tests for Duchenne/Becker muscular dystrophy, dystonia, and expanded panels for Charcot-Marie-Tooth disease and hereditary spastic paraplegia - Invitae Corporation (NYSE: NVTA), a genetic information company, today announced it now offers genetic testing for neuromuscular diseases, including Duchenne/Becker muscular dystrophy, dystonia, and pediatric neurodevelopmental syndromes. The company also expanded its panels for Charcot-Marie-Tooth disease and hereditary spastic paraplegia, progressive genetic diseases that affect motor and sensory pathways. Invitae now has nearly 100 carefully curated genes featured on its neuromuscular menu , from which clinicians can easily select a pre-curated gene panel, combine multiple panels, or customize their own panels based on the clinical need of their patients. "Genetic testing for neuromuscular disorders is important for the diagnostic care of individuals suffering from these disorders and for
Read more
October 7, 2015 Invitae Expands Its Offering for Rare Disease and Pediatric Conditions with Broader, Affordable Genetic Tests
- High-quality genetic tests now available for RASopathies, ciliopathies, and various congenital structural heart defects, patient pay price is $475 - - More panels for rare diseases to be introduced in coming months - nvitae Corporation (NYSE: NVTA) , a genetic information company, today announced that it has started to expand its offering of genetic tests for rare diseases and pediatric conditions, providing broader panels and new testing categories. Invitae’s new test panels for various congenital structural heart defects provide a broad, innovative option for patients with negative or uncertain chromosomal microarray results. Additionally, Invitae has expanded its test panels for two challenging pediatric disorders, the RASopathy syndromes, such as Noonan syndrome, and primary ciliary dyskinesia (PCD), a serious pediatric disorder of the respiratory system that often escapes early diagnosis. Invitae plans to continue to broaden its test menu for rare and pediatric conditions over
Read more
October 7, 2015 Invitae Expands Its Hereditary Cancer Offering
- Now offering new high-quality panels for gastric cancer, for common hereditary cancer, and for expanded breast, gynecologic, colon, and pancreatic cancer testing - Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it is releasing the next generation of comprehensive cancer panels, providing broader panels and new testing categories. Invitae has now expanded its cancer offering to include more than 40 testing panels. This new offering includes a mix of larger panels, such as expanded test panels for hereditary breast, gynecologic, colon, and pancreatic cancers, and new panels for common hereditary cancers and gastric cancer. The new test menu also includes smaller, focused test panels, such as Lynch syndrome and hereditary breast and ovarian cancer syndrome. Invitae testing also provides detection of unusual but important mutations such as the promoter mutations in APC , BMPR1A , GREM1 , PTEN , MLH1 , and TP53 , and previously difficult to detect
Read more
October 7, 2015 Invitae Expands Its Cardiology Offering to Provide More Comprehensive Testing for Patients and Their Families
- A wide range of high-quality, affordable genetic tests now available for hereditary cardiovascular disorders - Invitae Corporation (NYSE: NVTA), a genetic information company, today announced the expansion of its cardiology offering, including more than 30 cardiovascular test panels for arrhythmias, cardiomyopathies, aortopathies, familial hypercholesterolemia, pulmonary hypertension, and congenital heart disease. Genetic cardiac conditions may be difficult to diagnose. Often, the first evidence of a hereditary cardiac condition is the sudden death of an otherwise healthy person, sometimes in infancy or childhood. Invitae’s expanded cardiovascular test menu allows the company to provide first-line genetic testing for inherited arrhythmia and cardiomyopathy conditions, including sudden cardiac arrest or death, as well as inherited aortic diseases and familial hypercholesterolemia, one of the most common inherited cardiovascular conditions. This comprehensive cardiology offering
Read more
October 7, 2015 Invitae Expands Test Menu to Include Hundreds of New Genes, Dozens of New Test Panels for Cancer, Cardiology, Neuromuscular, Pediatrics, and Rare Disorders
SAN FRANCISCO-(BUSINESS WIRE)- Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will release the new content between now and the end of the year. Invitae is immediately expanding its menu with dozens of new test panels for hereditary cancer, cardiovascular, neuromuscular, pediatric, and other rare disorders. With this expanded test menu , Invitae will be able to provide clinicians, patients, and payers with high-quality genetic information for a greatly expanded number of genes and disorders, all at the same price and with rapid turnaround times. “We successfully increased our capacity to test for more than 600 genes, an increase from our initial plan of more than 500 genes, without increasing our prices. We are proud to now offer many more comprehensive and affordable cancer and cardiology genetic test panels, as well as expanded neuromuscular,
Read more
October 6, 2015 Invitae to Host Investor Conference Call on October 7, 2015 to Discuss Expanded Genetic Testing Menu
Invitae Corporation (NYSE: NVTA) , a genetic information company, today announced that it will host an investor conference call on Wednesday, October 7 at 4:30 p.m. Eastern / 1:30 p.m. Pacific. Invitae’s management team will discuss the company’s expanded genetic testing menu. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 55474881. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company’s website at invitae2016ir.q4web.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website. About Invitae Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests
Read more
September 21, 2015 Invitae Announces New Education Program to Accelerate the Use of Family History and Increase Awareness of Genetic Testing
- New survey shows that while celebrity stories drive awareness of cancer and genetics, more engagement is needed among patients, their families and their clinicians - A new survey released today shows 73 percent of Americans are aware of genetic testing for hereditary cancers – a significant increase over just a few years ago. Previous research found that in 2010 less than half of the Americans surveyed said they were aware of genetic testing. Dubbed the “Angelina Jolie Effect,” the current data highlight the far-reaching impact of Angelina Jolie’s public discussion of genetic testing for hereditary cancer. However, despite this heightened awareness of genetic testing, there remains confusion about how cancer is inherited, a lack of knowledge of family health history, and a strong desire for clinical guidance when pursuing genetic testing. Indeed, the vast majority of those surveyed (80%) said they would want their personal physician or a genetic counselor to provide access to
Read more
September 10, 2015 Invitae to Present at the 2015 Morgan Stanley Global Healthcare Conference
Invitae Corporation (NYSE:NVTA) today announced that members of the company’s management team will present at the 2015 Morgan Stanley Global Healthcare Conference on Friday, September 18, 2015 at approximately 8:45 a.m. Eastern / 5:45 a.m. Pacific in New York City . This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150910005443/en/ The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at invitae2016ir.q4web.com . A replay of the webcasts will be available shortly after the conclusion of the presentation and will be archived on the company’s website. About Invitae Invitae’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time
Read more
August 13, 2015 Invitae and Collaborators Announce Publication of New Data Showing the Clinical Actionability of Multi-Gene Panel Testing for Hereditary Breast and Ovarian Cancer Risk in JAMA Oncology
Invitae Corporation (NYSE: NVTA) , a genetic information company, and its collaborators announced the publication of new data describing the clinical actionability of multi-gene testing for hereditary breast and ovarian cancer (HBOC) risk in JAMA Oncology . The study was a collaboration among Massachusetts General Hospital , Harvard Medical School , Stanford University , Beth Israel Deaconess Medical Center and Invitae . In this paper, more than 1,000 patients were tested with multi-gene panels, and the clinical actions that would be considered were reviewed for all 63 patients testing positive for cancer genes other than BRCA1 or BRCA2. For more than half of these patients, the genetic test would suggest a change in care over and above any recommendations based on the patient’s personal and family history alone. For these patients’ family members, testing would be warranted, as over 70% would have a change in care considered if also found to be mutation positive. “Multi-gene panel
Read more
August 6, 2015 Invitae Raises Volume Guidance, Announces Second Quarter 2015 Financial Results
- Generated strong volume growth, accelerated R&D to expand beyond cancer - - Investing to gain scale and enable long-term profitability - - Conference call to be held today at 4:45 p.m. Eastern/1:45 p.m. Pacific - Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the second quarter ended June 30, 2015. The company has raised its guidance for billable tests delivered in 2015 to 16,000-18,000, up from its previous guidance of 14,000-17,000 billable tests delivered. “We’re pleased to report our progress in reducing COGS and increasing volume, content, and revenue. As we continue to deliver on these key initiatives, we’re taking an aggressive approach to investing in our competitive advantage in this new global market for comprehensive genetic testing,” said Randy Scott , chairman and CEO of Invitae . “We’re now moving into a new chapter for the company, focused on the path to profitability. We believe our investment in scaling up our production -
Read more
August 6, 2015 Invitae to Present at the Canaccord Genuity 35th Annual Growth Conference
Invitae Corporation (NYSE:NVTA) today announced that members of the company’s management team will present at the Canaccord Genuity 35th Annual Growth Conference on Thursday, August 13, 2015 at approximately 3:30 p.m. Eastern / 12:30 p.m. Pacific in Boston, Massachusetts . The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at invitae2016ir.q4web.com. A replay of the webcasts will be available shortly after the conclusion of the presentation and will be archived on the company’s website. About Invitae Invitae’s (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic service comprising more
Read more
July 23, 2015 Invitae to Announce Second Quarter 2015 Financial Results and Host Conference Call on August 6, 2015
Invitae Corporation ( NYSE: NVTA ), a genetic information company, today announced that it will report its second quarter 2015 financial results on Thursday, August 6, 2015 and will host a conference call that day at 4:45 p.m. ET / 1:45 p.m. PT to discuss the financial results and recent developments. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 85327941. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company’s website at invitae2016ir.q4web.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website. About Invitae Invitae’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers,
Read more
July 22, 2015 Invitae Announces Online Publication of Data Comparing Traditional and Multi-Gene Panel Testing for Hereditary Breast and Ovarian Cancer in The Journal of Molecular Diagnostics
Invitae Corporation (NYSE:NVTA) , a genetic information company, and collaborators announced the publication of data directly comparing traditional and multi-gene panel testing in more than 1,000 patients in The Journal of Molecular Diagnostics . The data, published online today, are from a collaboration among Invitae , Massachusetts General Hospital , Harvard Medical School , and the Stanford University School of Medicine . The Journal of Molecular Diagnostics is the official journal of the Association for Molecular Pathology , the society of professionals involved in molecular and genomic laboratory medicine. The published data show that Invitae’s next generation DNA sequencing platform achieves high sensitivity and specificity compared to traditional genetic tests from other labs. The authors examined the analytic performance of Invitae’s methods on 29 cancer risk genes, concluding that Invitae was able to detect 100% of the comparable DNA alterations detected by traditional
Read more
June 1, 2015 Invitae Launches New Patient Pay Price of $475 for Its Full Menu of Genetic Tests
- Company’s goal is to make genetic testing more affordable and accessible - - Applies to full menu of testing in cancer, cardiology, neurology, pediatric genetics, hematology and other rare conditions - Invitae Corporation (NYSE: NVTA) , a genetic information company, announced today the launch of its new patient pay price for its full menu of genetic tests at $475 per indication. This new price covers all of Invitae’s offerings in cancer, cardiology, neurology, pediatric genetics, hematology and other rare conditions. It is exclusively for patients who register online, pay up front for genetic services themselves and whose clinician has ordered the testing online. This new, more affordable price is intended to help Invitae serve more patients, including those who do not meet coverage policies for testing, those with high-deductible plans and those not covered by insurance. For example, this new pricing program provides an affordable test for women who previously tested negative for
Read more
May 13, 2015 Invitae and Collaborators to Present New Data at the 2015 American Society of Clinical Oncology Annual Meeting Focusing on the Clinical Utility of Multi-Gene Panel Tests for Hereditary Breast and Ovarian Cancer
- Study demonstrates that Invitae’s multi-gene test yields clinically actionable findings for substantially more patients than does traditional single-gene testing - Invitae Corporation (NYSE:NVTA), a genetic information company, announced that new data will be presented during the 51st American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation, “Clinical Impact of Multi-Gene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment” (Abstract 1513), will be presented as a poster discussion on Monday, June 1 by Leif W. Ellisen, MD, PhD, program director of breast medical oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School. The study was conducted as a collaboration between Invitae , Massachusetts General Hospital , the Stanford University Cancer Institute and Beth Israel Deaconess Medical Center . The goal of the study was to evaluate the clinical utility of multi-gene hereditary cancer tests in a
Read more
May 12, 2015 Invitae Announces First Quarter 2015 Financial Results and Highlights
- Company accelerates R&D and reports strong volume growth -
- Announces new pricing programs to make genetic testing more affordable and accessible - Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the first quarter ended March 31, 2015 . Highlights for the quarter include: Generated revenue of $1.2 million in the first quarter, an increase of 40% over revenue in the fourth quarter of 2014. Increased volume by delivering more than 2,200 billable reports, an increase of 23% over volume in the fourth quarter of 2014, and accessioning more than 2,700 samples in the first quarter. Reported cost of goods sold (COGS) of less than $1,200 per sample accessioned for the quarter. Expect to see reductions in the average cost per billable test of 30-40% in Q2 as a result of a series of laboratory process improvements that were implemented in Q1. Expanded its test catalog to include four new cancer-related genes, as well as full coverage of CHEK2, a
Read more
April 28, 2015 Invitae to Announce First Quarter 2015 Financial Results and Host Conference Call May 12, 2015
Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it will report its first quarter 2015 financial results on Tuesday, May 12, 2015 . Invitae’s management team will host a conference call on Tuesday, May 12, 2015 at 4:45 p.m. ET / 1:45 p.m. PT to discuss the financial results and recent developments. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 26346322. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company’s website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website. About Invitae Invitae’s (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on
Read more
April 27, 2015 Invitae Appoints Robert Nussbaum, M.D., as Chief Medical Officer
- Medical genetics pioneer from UCSF to join executive team to lead medical organization - Invitae Corporation (NYSE:NVTA), a genetic information company, today announced the appointment of Robert L. Nussbaum, M.D. as Chief Medical Officer; such appointment will become effective August 1, 2015. As a board-certified internist and medical geneticist, Dr. Nussbaum has dedicated his career to improving the care of adults and children with hereditary disorders. Dr. Nussbaum was most recently chief of the Division of Genomic Medicine at UCSF Health and has played leadership roles in the Cancer Genetics and Prevention Program and in the Program in Cardiovascular Genetics. As a member of the UCSF Institute for Human Genetics for the past nine years, Dr. Nussbaum will bring to Invitae extensive expertise in using genetic information to better healthcare by improving outcomes, lowering costs, and promoting education. Dr. Nussbaum, a member of the Institute of Medicine and a fellow at the
Read more
March 26, 2015 Invitae Presents New Data Demonstrating Use of Next-Generation Sequencing for Multi-Gene Panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting
- Company also expands test catalog; now offers full coverage of CHEK2 gene and four new cancer-related genes - Invitae Corporation (NYSE:NVTA), a genetic information company, is presenting seven posters at the 2015 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, including data demonstrating the use of next-generation sequencing (NGS) technology in genetic testing, a proposed variant classification system based on ACMG guidelines, and genetic testing case studies. Invitae also announced that it has expanded its test catalog to include four new cancer-related genes, as well as full coverage of CHEK2, a gene associated with increased cancer risk. “The field of genetics is changing rapidly, and the discovery of the correlation between genes and hereditary disorders is vastly improving patient care. The ability to order full CHEK2—an important option for patients with a personal and family history of breast cancer—is a great example of this,” said Invitae’s
Read more
March 17, 2015 Invitae to Present Seven Posters Highlighting New Data on the Use of Next-Generation Sequencing for Multi-Gene Panels at the 2015 American College of Medical Genetics Annual Clinical Genetics Meeting
Invitae Corporation (NYSE:NVTA), a genetic information company, today announced it will be presenting seven posters at the 2015 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Salt Lake City . The titles and schedule of the poster presentations are as follows: Poster Session 1: Thursday, March 26, 10:30 a.m. – 12:00 p.m. MT Poster #105: Next-Generation Panel vs. Traditional BRCA1/2 Testing: Challenging Variants, Classification Under the Draft ACMG ISV Guidelines and Potential Actionability of Findings Poster #139: Expanding the Clinical Spectrum of Mosaic Mutations in TP53 Identified by Next-Generation Sequencing: A Retrospective Analysis Poster #247: Early Onset Charcot-Marie-Tooth Disease with Diaphragmatic Weakness: a Case Report of an Autosomal Recessive MFN2 Compound Heterozygote Poster #383: Discovery and Clinical Interpretation of a SMAD4 Retrotransposon Using Next-Generation Sequencing Poster #415: A Weighted, Score-Based Variant Classification
Read more
March 10, 2015 Invitae Announces Fourth Quarter and 2014 Year-End Financial Results and Highlights and Provides 2015 Outlook
- Company demonstrates early progress towards achieving its goal of making genetic information more affordable and accessible - Invitae Corporation (NYSE:NVTA) today reported financial and operating results for the fourth quarter and year ended December 31, 2014. Highlights for the quarter and year include: Delivered more than 1,800 billable reports in the fourth quarter and more than 3,600 billable reports during 2014. Improved cost of goods sold (COGS) by driving the average cost per billable report to under $1,200 in the fourth quarter. The average cost per billable report in 2014 was over $1,500 . Generated $876,000 in revenue in the fourth quarter and $1.6 million for the full year. Secured reimbursement contracts with Blue Shield of California and SelectHealth, and became licensed for Medicare . Published data in the Journal of Clinical Oncology based on a collaboration with Stanford University and presented data at the San Antonio Breast Cancer Symposium based on a
Read more
February 24, 2015 Invitae to Announce Fourth Quarter and Year-End 2014 Financial Results and Host Conference Call on March 10, 2015
Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its fourth quarter and year-end 2014 financial results on Tuesday, March 10, 2015. Invitae’s management team will host a conference call on Tuesday, March 10, 2015 at 4:45 p.m. ET/ 1:45 p.m. PT to discuss the financial results and recent developments. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 94713369. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company's website at ir.invitae.com . A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. About Invitae Invitae’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people.
Read more
February 18, 2015 Invitae Announces Completion of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Invitae Corporation (NYSE:NVTA), a genetic information company, announced today the closing of its initial public offering of 7,302,500 shares of common stock at an initial public offering price of $16.00 per share, which included 952,500 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock. Total gross proceeds from the offering were approximately $116.8 million , before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Invitae . Invitae’s common stock is listed on the New York Stock Exchange under the symbol “NVTA.” J.P. Morgan Securities LLC acted as the sole book-running manager for the offering. Cowen and Company, LLC and Leerink Partners LLC acted as co-managers. Registration statements relating to these securities have been filed with the Securities and Exchange Commission and became effective on February 11, 2015 . Copies of
Read more
February 11, 2015 Invitae Announces Pricing of Initial Public Offering of Common Stock
Invitae Corporation (NYSE: NVTA), a genetic information company, announced today the pricing of its initial public offering of 6,350,000 shares of its common stock at an initial offering price of $16.00 per share, for total gross proceeds of $101.6 million before deducting underwriting discounts and commissions and other offering expenses. The shares of Invitae’s common stock are expected to begin trading on the New York Stock Exchange under the symbol “NVTA” on February 12, 2015 . All of the shares in the offering are being offered by Invitae . The offering is expected to close on or about February 18, 2015 , subject to customary closing conditions. In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 952,500 shares of common stock at such offering price, less customary underwriting discounts and commissions. J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering. Cowen and Company, LLC and Leerink Partners
Read more
January 26, 2015 Invitae announces settlement in lawsuit with Myriad Genetics
SAN FRANCISCO — January 26, 2015 —Invitae Corporation, a genetic information company, announced today that it had reached a settlement with Myriad Genetics, Inc., the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, and Endorecherche, Inc. in their patent dispute concerning Invitae’s genetic testing for the BRCA1, BRCA2 and MUTYH genes (MDL Case No. 2:14-CV-02510; Civil Case No. 2:14-cv-00153-RJS (D. Utah).) The parties agreed to dismiss with prejudice their claims and counterclaims against each other in this action, that Invitae would be granted a covenant not to sue with respect to the patents–in–suit, and that the parties would bear their own costs. This settlement will resolve all pending litigation between Invitae and the other parties. About Invitae      Based in San Francisco, Invitae’s mission is to bring comprehensive genetic information into mainstream medical
Read more
January 9, 2015 Invitae Corporation files registration statement for proposed initial public offering
SAN FRANCISCO — January 9, 2015 —Invitae Corporation announced today that it has filed a registration statement on Form S‐1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Invitae intends to apply to list its common stock on The New York Stock Exchange under the symbol “NVTA.” J.P. Morgan Securities LLC is acting as the sole book‐running manager for the offering. Cowen and Company, LLC and Leerink Partners LLC are acting as co‐managers. This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at (866) 803‐9204. A registration statement relating to these securities has been filed with the SEC but has
Read more

DISCLAIMER

The information in the press releases, presentations, webcasts and publications is archival and should be considered accurate only as of its date. We disclaim any obligation to supplement or update the information in these documents, presentations or webcasts.

FORWARD-LOOKING STATEMENTS

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including those risks and uncertainties detailed from time to time in Invitae Corporation’s periodic filings with the Securities and Exchange Commission. Invitae Corporation specifically disclaims any obligation to update any forward-looking statements.

Forward Looking Statements
NYSE: NVTA 16.70 -0.02 -0.12% Volume: 1,196,250 20 minute delay September 24, 2018

Investor Toolkit

Feature Presentation

Email Alerts

Sign up to receive Invitae financial information by email.
Email Address: *
I'D LIKE TO RECEIVE EMAILS ABOUT: *




 
Enter the code shown above.

Investor Contact

1400 16th St.
San Francisco, CA, 94103
Email: ir@invitae.com